Close Menu

NEW YORK (GenomeWeb) – Intermountain Healthcare spinout Navican Genomics today said it closed a $15 million Series A financing round, led by Intermountain.

The financing will go toward the commercialization and expansion of Navican's precision cancer care offering, including the commercialization of its TheraMap solution, which leverages precision genomics, clinical analytics, and patient services for cancer management.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.